Preclinical Humanized CD39 Mouse Model

Humanized Immune Checkpoint Mouse Models

Design of the hCD39 mouse

The humanized CD39 model, developed by Knockin at the mouse CD39 locus, expresses a chimeric CD39 with a human extracellular and murine transmembrane and intracellular domains. The design also gives access to CD39 conditional Knockout mice.

Applications in immuno-oncology

The hCD39 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint CD39 in fully immunocompetent mice.

Access to conditional CD39 Knockout mouse:
The conditional Knockout model allows the tissue-specific assessment of compound's specificity and toxicity.


Request a quote here to get pricing, offers and hCD39 model information by phone or email.


hCD39 features

  • The CD39 extracellular domain is entirely humanized
  • Physiological regulation and expression pattern of the human CD39
  • Fully functional mouse immune system
  • Lack of expression of the murine target gene, thus avoiding cross-reactivity

hCD39 validation*

The model has been co-validated by genOway and our partners of the precompetitive consortium of company leaders in immuno-oncology and immunotherapy.

hCD39 ICP model validation 1

hCD39 expression pattern recapitulates mCD39

hCD39 and mCD39 expression on freshly isolated splenocytes on A) dendritic cells (CD3-CD19-CD11b+CD11c+), B) B cells (CD3-CD19+), and C) Tregs (viable, CD3+CD4+CD25+Foxp3+).

hCD39 ICP model validation 2

hCD39 is functional: anti-human CD39 specifically reduces human CD39 activity

Freshly isolated splenocytes from A) Wild-type and B) hCD39 mice, stimulated with anti-mCD39, anti-hCD39 or inhibitor control ARL (ectonucleotidases inhibitor) for 1h. ATP level was measured by CellTiter-Glo® luminescent cell assay following ATP addition. Results are expressed as mean±SD. Two-way ANOVA (**p<0.01; ***p<0.001; ****p<0.0001)

* For more validation data please contact us.


Michael C Warren, Stephan Matissek, Matthew Rausch, Marisella Panduro, R J Hall, Austin Dulak, David Brennan, Sonia Das Yekkirala, Secil Koseoglu, Ricard Masia, Yu Yang, Navamallika Reddy, Robert Prenovitz, Jamie Strand, Tauqueer Zaidi, Erik Devereaux, Célia Jacoberger Foissac, John Stagg, Benjamin H Lee, Pamela Holland, Vito J Palombella, Andrew C Lake.
SRF617 Is a Potent Inhibitor of CD39 with Immunomodulatory and Antitumor Properties.
Immunohorizons. 2023 May 1


Ready to be shipped to your lab

  • Cohorts available upon request
  • Studies can be carried out at your site or at your favorite CRO
  • SOPF certification and worldwide delivery by professional breeders
  • Models provided with FTO on patent-protected technologies used for model generation

Are you looking for another target?
Follow this link, humanized immune checkpoint (ICP) mouse models, or contact us.